Antibody-drug conjugates in breast cancer: current evidence and future directions
Abstract Antibody-drug conjugates (ADCs) are a rapidly evolving class of antitumor drugs and have already revolutionized the treatment strategy of many hematologic and solid cancers. So far, trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG) and datopotamab der...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BMC
2025-03-01
|
| 叢編: | Experimental Hematology & Oncology |
| 主題: | |
| 在線閱讀: | https://doi.org/10.1186/s40164-025-00632-9 |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|